|
TIPRL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.97439999483873E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73527999999257E-05 |
| Normal-vs-Stage2 |
2.22970000000045E-05 |
| Normal-vs-Stage3 |
2.81719999994934E-07 |
| Normal-vs-Stage4 |
8.171700E-04 |
| Stage1-vs-Stage2 |
3.850400E-01 |
| Stage1-vs-Stage3 |
1.441550E-01 |
| Stage1-vs-Stage4 |
8.025000E-01 |
| Stage2-vs-Stage3 |
8.453400E-01 |
| Stage2-vs-Stage4 |
6.535800E-01 |
| Stage3-vs-Stage4 |
4.675000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.40259999965076E-07 |
| Normal-vs-AfricanAmerican |
2.209500E-02 |
| Normal-vs-Asian |
2.019200E-04 |
| Caucasian-vs-AfricanAmerican |
2.991000E-01 |
| Caucasian-vs-Asian |
7.816200E-01 |
| AfricanAmerican-vs-Asian |
4.570400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.64549999970687E-07 |
| Normal-vs-Female |
3.88039999998924E-06 |
| Male-vs-Female |
2.057000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.80899999999906E-05 |
| Normal-vs-Age(41-60Yrs) |
3.65110000011271E-08 |
| Normal-vs-Age(61-80Yrs) |
6.1027999999963E-05 |
| Normal-vs-Age(81-100Yrs) |
3.549900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.025610E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.757400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.871000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.345800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.834600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.098000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.596100E-02 |
| Classical-VS-Follicular |
3.618400E-02 |
| Classical-VS-Other |
6.116400E-02 |
| Classical-VS-Normal |
1.169030E-04 |
| Tall-VS-Follicular |
6.947400E-01 |
| Tall-VS-Other |
3.229800E-01 |
| Tall-VS-Normal |
4.03739999998987E-06 |
| Follicular-VS-Other |
2.928200E-01 |
| Follicular-VS-Normal |
2.62920000004829E-06 |
| Other-VS-Normal |
4.426700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.15420000410683E-08 |
| Normal-vs-N1 |
2.40669999999055E-05 |
| N0-vs-N1 |
8.325600E-01 |
|
|
